Lymphedema Global Clinical Trials Review, H2, 2011 (Related Reports)

Lymphedema Global Clinical Trials Review, H2, 2011


November 30, 2011
73 Pages - SKU: GBDT6713611
License type:
Online Download      US $1,000.00
Global Site License      US $3,000.00
Peptides in Oncology: Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
Peptides in Oncology: Drug Pathway Analyzer 2014 Extra value: One year of free online updates included with this product There are today at least 188 peptide drugs known to affect more than 216 specific intracellular signaling pathways  |  read more...
$5,622.50
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This  |  read more...
$2,500.00
Molecular Spectroscopy Market by Technology [NMR (FT, Continuous Wave), UV-Visible (Photodiode Array, Handheld), IR (Terahertz, Benchtop), NIR (FT-NIR) Raman (SERS, TERS, FT Raman)] & by Application (Pharmaceutical, Food) - Forecast to 2018
4/4/2014 | published by: MarketsandMarkets
Molecular Spectroscopy Market by Technology [NMR (FT, Continuous Wave), UV-Visible (Photodiode Array, Handheld), IR (Terahertz, Benchtop), NIR (FT-NIR) Raman (SERS, TERS, FT Raman)] & by Application (Pharmaceutical, Food) - Forecast to 2018 Over the  |  read more...
$4,650.00
Severe Psoriasis - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
Severe Psoriasis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Severe Psoriasis - Pipeline Review, H1 2014’, provides an overview of the Severe Psoriasis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Severe  |  read more...
$2,000.00
Pertussis - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
Pertussis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Pertussis - Pipeline Review, H1 2014’, provides an overview of the Pertussis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative  |  read more...
$2,000.00
Yellow Fever - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
Yellow Fever - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Yellow Fever - Pipeline Review, H1 2014’, provides an overview of the Yellow Fever’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Yellow  |  read more...
$2,000.00
Tourette Syndrome - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
Tourette Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Tourette Syndrome - Pipeline Review, H1 2014’, provides an overview of the Tourette Syndrome’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tourette  |  read more...
$2,000.00
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
3/27/2014 | published by: GlobalData
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017 Summary With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on  |  read more...
$5,995.00
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022
3/27/2014 | published by: GlobalData
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022 Summary Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, and is one of the most common rheumatic conditions throughout the world.  |  read more...
$3,995.00
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
4/1/2014 | published by: FirstWord
Introduction Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in  |  read more...
$4,995.00